Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer

類似資料

• Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
  著者:: Ortiz, Michael V., 等
  出版事項: (2020)
• Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
  著者:: Takeda, Masayuki, 等
  出版事項: (2019)
• SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
  著者:: Cabanillas, Maria E, 等
  出版事項: (2020)
• Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
  著者:: Andreev-Drakhlin, Alexander, 等
  出版事項: (2020)
• Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
  著者:: Guo, Robin, 等
  出版事項: (2019)